An adverse tumor-protective effect of IDO1 inhibition
Juliana C.N. Kenski(The Netherlands Cancer Institute), Daniel S. Peeper(The Netherlands Cancer Institute), Pierre-René Körner(The Netherlands Cancer Institute), Alexandra M. Terry(Genmab (United States)), David W. Vredevoogd(The Netherlands Cancer Institute), Jean‐Christophe Marine(Vlaams Instituut voor Biotechnologie), Thomas Kuilman(The Netherlands Cancer Institute), Sebastiaan M. Schieven(The Netherlands Cancer Institute), Fabricio Loayza‐Puch(German Cancer Research Center), Joleen J.H. Traets(The Netherlands Cancer Institute), Xinyao Huang(The Netherlands Cancer Institute), Alex van Vliet(The Netherlands Cancer Institute), Sofía Ibáñez-Molero(Oncode Institute), Marjolein de Bruijn(The Netherlands Cancer Institute), Joanna Poźniak(VIB-KU Leuven Center for Cancer Biology), Pierre Lévy(The Netherlands Cancer Institute), Oscar Krijgsman(The Netherlands Cancer Institute), Reuven Agami(Erasmus MC), Meike E. W. Logtenberg(The Netherlands Cancer Institute), Beaunelle de Bruijn(Amsterdam University Medical Centers), Ton N. Schumacher(Leiden University Medical Center), Judith M. Müller(The Netherlands Cancer Institute), Colin R. Goding(University of Oxford)
Cited by 32
Related Papers
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
BRAFE600-associated senescence-like cell cycle arrest of human naevi
|Nature|2005|2.1k
The essence of senescence: Figure 1.
|Genes & Development|2010|2k
Regulation of the p27Kip1 tumor suppressor by miR‐221 and miR‐222 promotes cancer cell proliferation
|The EMBO Journal|2007|812
Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive Melanoma
|Journal of Clinical Oncology|2013|799